CNS Drug Discoveries: what the future holds

Table of Contents

EXECUTIVE SUMMARY

• Figure 1. Global CNS Market (US$68.7 billion)
• Competitor Ratio Analysis - Drugs
  • CNS Drugs Analysed for Launch by 2012 - Therapeutic Category
• Competitor Ratio Analysis - Companies
  • CNS Drugs Analysed for Launch by 2012 -Major Pharma Companies
  • Pharmaceutical Companies and products analysis in this report
  • CNS Drugs Analysed for Launch by 2012 -Speciality Pharma & Biotech Companies
  • Biotechnology and Specialty Pharma Companies and products analysis in this report
• About the Author

ATTENTION DEFICIT HYPERACTIVITY DISORDER

• EXECUTIVE SUMMARY
• THE FACTS
  • What is ADHD and why are we interested in it?
    • Symptoms of ADHD subtype
    • Rates of Co-morbid Conditions among Children with ADHD
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • The addressable ADHD market will have show 6.5% CAGR over the period 2005-2012
    • Summary of patient population forecasts 2005A-2012E
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

GLOBAL ADHD MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • Global sales split (2005A)
  • US market
    • ADHD US drugs sales split (2005A)
  • European market
    • ADHD European drugs sales split (2005A)
  • Japanese market
  • The major players
    • Market share of ADHD players by sales (Dec 2005A)
  • Players and Products in 2005 & 2006
  • Players and Products in 2012
    • Market share of ADHD players by sales (Dec 2012E)
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of leading ADHD drugs
  • Current Products Patent Exposure
• ANALYSIS OF LEADING BRANDS
  • Stimulants
  • Non-Stimulant
• STIMULANTS
  • Adderall and Adderall XR (Shire)
  • Concerta and Concerta XL (Johnson & Johnson)
  • Competitor Ratio Analysis
  • Daytrana (Shire)
  • Focalin/Focalin XR (Novartis)
  • Ritalin/Ritalin LA (Novartis)
  • Metadate ER/Equasym and Metadate CD/Equasym XL (UCB)
• NON STIMULANT
  • Strattera (Eli Lilly)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading ADHD Drugs
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat ADHD
• ANALYSIS OF PHASE III DRUGS
  • New Drugs in Phase III Development to Treat ADHD
  • Non-Stimulant
  • Stimulant
  • Connexyn (Shire)
    • p-value of ADHD-RS Efficacy of SPD503 versus placebo in Phase III trials
    • Changing in ADHD Rating Score Connexyn (Study 301) and Strattera (Study 3468)
  • NRP104 (Shire)
  • SPD465 (Shire)
• GLOBAL SALES FORECASTS OF PHASE III ADHD DRUGS 2006 - 2012
  • Sales Forecasts of Phase III Developmental ADHD Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat ADHD
  • NS2359 (GSK, NeuroSearch)
  • CX717 (Cortex Pharmaceuticals)
  • PRX-00023
  • SGS742
  • Abilify
• GLOBAL SALES FORECASTS OF PHASE II ADHD DRUGS 2006 - 2012
  • Sales Forecasts of Phase 2 Developmental ADHD Drugs
  • Model assumptions
• COMPETITOR RATIO ANALYSIS
  • CR Analysis of ADHD Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of ADHD Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the ADHD Market by 2012
  • Winners
  • Losers
• DISCONTINUATION OF DRUGS
  • ADHD drugs discontinued from clinical development
• ADHD APPENDIX 1
  • Assessment of ADHD Criteria
• ADHD APPENDIX 2
  • Phase transition probability
    • Probability of launch
• ADHD APPENDIX 3
  • Patient Model
    • Summary of US ADHD Patient Population Forecasts
    • Summary of Europe (Top 5) ADHD Patient Population Forecasts
    • Summary of Japan ADHD Patient Population Forecasts
• ADHD APPENDIX 4
  • Global ADHD Drugs Sales 2005-20012
    • Global ADHD Drug Sales 2005A-2012E (US$ million)
• ADHD APPENDIX 5
  • Competitor Ratio Analysis Criteria
    • Key ADHD Drugs on the Market by 2012
• ADHD GLOSSARY
• ADHD REFERENCES
• ACRONYMS

DEPRESSION

• EXECUTIVE SUMMARY
• THE FACTS
  • What is depression and why are we interested in it?
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • Summary of patient population forecasts in seven major markets (2005A-2012E)
  • Model assumptions
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS
• GLOBAL ANTIDEPRESSANT MARKET
  • Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • Global sales by region (2005A)
  • US market
    • Antidepressant US drugs sales by (2005A)
  • European market
    • European Antidepressant sales by (2005A)
  • ROW/Japanese market
  • The Major Players Products in 2005 & 2006
    • Market share of Antidepressant players by sales (Dec 2005A)
  • The Major Players and Products in 2012
    • Market share of Antidepressant Players by sales (Dec 2012E)
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of leading antidepressant drugs
  • Patent Exposure of Current Products
    • Patent Exposure of Leading Antidepressant Brands
• ANALYSIS OF LEADING BRANDS
• Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Lexapro/Cipralex (Forest/Lundbeck)
  • Prozac (Eli Lilly)
  • Zoloft (Pfizer)
• Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
  • Cymbalta (Eli Lilly)
  • Effexor (Wyeth)
• Noradrenaline and Dopamine Reuptake Inhibitors (NDRIs)
  • Wellbutrin (GlaxoSmithKline)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading Antidepressant Drugs
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat Depression and Anxiety Related Disorders
• ANALYSIS OF PHASE III DRUGS
  • New Drugs in Phase III Development to Treat Depression and Anxiety
  • Phase III drugs
  • Other Phase III drugs of interest

INSOMNIA

• EXECUTIVE SUMMARY
• THE FACTS
  • What is insomnia and why are we interested in it?
• PATIENT STATISTICS
  • Summary of insomnia patient population in top 5 European countries
• PATIENT MODEL
  • The addressable insomnia market will have a CAGR 2005-2012 = 5.9%
  • Patient population and sub-types of insomnia
• Summary of patient population (for top seven countries) forecasts
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPNERS

GLOBAL INSOMNIA MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • US market
    • Insomnia US drugs sales split (2005A)
  • European market
    • Insomnia European drugs sales split (2005A)
  • Japanese market
    • Insomnia Japanese drugs sales split (2005A)
  • The major players
    • Market share of insomnia players by sales (Dec 2005A)
  • Players and Products in 2005
  • Players and Products in 2012
    • Market share of insomnia players by sales (Dec 2012E)
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of Leading Brands
  • Current Products Patent Exposure
    • Patent exposure of leading brands
• ANALYSIS OF LEADING BRANDS
  • GABA-A Receptor Agonists
  • Melatonin Receptor Agonist
• GABA-A Receptor Agonists
  • Ambien/Stilnox/Myslee and Ambien CR (sanofi-aventis)
  • Lunesta (Sepracor)
  • Sonata (King Pharmaceuticals)
• Melatonin Receptor Agonist
  • Rozerem (Takeda)
    • Distribution of ML-1 and ML-2 receptors
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading Insomnia Drugs (US$ million)
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat Insomnia
• ANALYSIS OF PHASE III DRUGS
  • Drugs in Phase III Development to Treat Insomnia
  • GABA-A Receptor Agonists
  • Histamine Receptor Antagonist
  • 5-HT2A Receptor Antagonist
  • Melatonin Receptor Agonist
  • indiplon (Neurocrine Biosciences)
  • gaboxadol (Lundbeck)
  • Silenor (Somaxon)
  • Eplivanserin (sanofi-aventis)
    • Effect of eplivanserin on sleep parameters in Phase IIb trial
  • VEC-162 (Vanda Pharmaceuticals)
    • Efficacy of VEC-162 in transient insomnia trials
• GLOBAL SALES FORECASTS OF PHASE III INSOMNIA DRUGS 2006 - 2012
  • Sales Forecasts of Phase III Developmental Insomnia Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat Insomnia
  • 5-HT2A Receptor Antagonists
  • GABA-A Receptor Modulator
  • Melatonin Analogue
• 5-HT2A RECEPTOR ANTAGONISTS
  • M100907 (sanofi-aventis)
  • Pruvanserin (Eli Lilly)
• GABA-A MODULATORS
  • NG2-73 (Neurogen)
• MELATONIN ANALOGUE
  • PD-6735 (Phase II Discovery)
• GLOBAL SALES FORECASTS OF PHASE II INSOMNIA DRUGS 2006 - 2012
  • Sales Forecasts of Insomnia Drugs in Phase III
  • Model assumptions
    • CR Analysis of Insomnia Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of Insomnia Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the Insomnia Market by 2012
  • Winners
  • Losers
• DISCONTINUATION OF DRUGS
• INSOMNIA APPENDIX 1
  • Analysis of clinical trial data
• INSOMNIA APPENDIX 2
  • Phase transition probability
    • Probability of launch
• INSOMNIA APPENDIX 3
  • Patient Model
    • Summary of US Insomnia Patient Population Forecasts
    • Summary of Europe (Top 5) Insomnia Patient Population Forecasts
    • Summary of Japan Insomnia Patient Population Forecasts
• INSOMNIA APPENDIX 4
  • Global Drug Sales 2005-2012 (US$ million)
• INSOMNIA APPENDIX 5
  • Competitor Ratio Analysis Criteria
    • Key insomnia drugs due to be launched by 2012
• INSOMNIA GLOSSARY
• INSOMNIA REFERENCES
• Acronyms

Multiple Sclerosis

• EXECUTIVE SUMMARY
• THE FACTS
  • What is MS and why are we interested in it?
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
  • MS categories
    • Types of MS
• PATIENT MODEL
  • The treatable MS patient population will have a CAGR 2005-2012 = 4.6%
    • Summary of patient population forecasts
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

GLOBAL MS MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • Global sales split (2005A)
  • US market
    • MS US drugs sales split (2005A)
  • European market
    • MS European drugs sales split (2005A)
  • Japanese market
  • The major players
    • Market share of MS players by sales (Dec 2005A)
  • Players and Products in 2005 & 2006
  • Players and products in 2012
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of Leading MS Agents
  • Current Products Patent Exposure
    • Patent Exposure of Leading Brands
• ANALYSIS OF LEADING BRANDS
  • Disease-modifying agents
• Disease-modifying agents
  • Avonex (Biogen Idec/Genzyme)
  • Betaferon/Betaseron (Berlex/Schering AG)
  • Copaxone (Teva)
  • Rebif (Serono)
  • Tysabri
  • Novantrone (Serono)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005-2012
  • Sales Forecasts of Current Leading MS Drugs
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat MS
• ANALYSIS OF PHASE III DRUGS
  • New Drugs in Phase III Development to Treat MS
  • Disease-modifying agents
  • MS Symptoms
  • Campath (Genzyme/Schering AG)
  • FTY720 (Novartis)
  • Laquinimod (Teva/Active Biotech)
  • MBP8298 (BioMS)
  • Mylinax (Serono/Ivax)
  • Rituxan (Genentech/Biogen Idec/Roche/Chugai/Zenyaju Kogyo)
  • Teriflunomide (sanofi-aventis)
• MS Symptoms
  • Neurelan (Elan/Acorda)
    • Trial MS-F202: Timed 25-foot walk response rate of MS patients treated with Fampridine SR
• GLOBAL SALES FORECASTS OF PHASE III MS DRUGS 2006-2012
  • Sales Forecasts of Phase III Developmental MS Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat MS
  • Disease-modifying agents
  • Vaccines
• Disease-modifying agents
  • ABT-874 (Abbott)
  • ATL1102 (Antisense/ISIS pharmaceuticals)
  • BG-12 (Biogen Idec)
  • Daclizumab (Biogen Idec/BioPharma)
  • SB-683699 (GlaxoSmithKline/Tanabe Seiyaku)
• Vaccines
  • NeuroVax (TIRC)
  • Tovaxin (Opexa Therapeutics)
  • Other Interesting Phase II Drugs
• GLOBAL SALES FORECASTS OF PHASE II MS DRUGS 2006 - 2012
  • Sales Forecasts of Phase II Developmental MS Drugs
  • Model assumptions
• COMPETITOR RATIO ANALYSIS - PRODUCTS
  • CR Analysis of MS Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of MS Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
  • Summary of Key Companies and Drugs in the MS Market by 2012
  • Winners
  • Losers
• DISCONTINUATION OF DRUGS
  • MS Drugs Discontinued from Clinical Development
• MS APPENDIX 1
  • Clinical diagnostic test for MS
• MS APPENDIX 2
  • Expanded Disability Status Scale (EDSS)
• MS APPENDIX 3
  • Phase transition probability
    • Probability of launch
• MS APPENDIX 4
  • Patient Model
    • Summary of US MS Patient Population Forecasts
    • Summary of Europe (Tope 5) MS Patient Population Forecasts
    • Summary of Japan MS Patient Population Forecasts
• MS APPENDIX 5
  • Global MS Drugs Sales 2005-20012
    • Global MS Drug Sales 2005A-2012E
• Ms APPENDIX 6
  • Competitor Ratio Analysis Criteria
    • Key MS Drugs on the Market by 2012
• MS GLOSSARY
• MS REFERENCES
• ACRONYMNS

NEURODEGENERATION

• EXECUTIVE SUMMARY
• THE FACTS
  • What is neurodegeneration and why are we interested in it?
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • The addressable AD and PD patient population will grow by 2% per annum
    • Summary of AD patient population forecasts 2005A-2012E
    • Summary of PD patient population forecasts 2005A-2012E
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

GLOBAL AD/PD MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • AD and PD Global sales split (2005A)
  • AD Global sales split (2005A)
  • PD Global sales split (2005A)
• US market
  • AD US drugs sales split (2005A)
  • PD US drugs sales split (2005A)
• European market
  • AD European drugs sales split (2005A)
  • PD European drugs sales split (2005A)
• Japan
  • Split between AD and PD in Japan (2005A)
• The major players
  • Market Share of AD players by sales (Dec 2005A)
  • Market Share of PD players by sales (Dec 2005A)
• Players and Products in 2012
  • Market Share of AD players by sales (Dec 2012E)
• Players and Products in 2012
  • Market Share of PD players by sales (Dec 2012E)
• CURRENT AD TREATMENTS
• CURRENT PD TREATMENTS
  • Leading Brands
    • Comparison of leading AD drugs
    • Comparison of leading PD drug classes
  • Patent Exposure of Current Products
    • Patent Exposure of Leading AD Brands
    • Patent Exposure of Leading PD Brands
• ANALYSIS OF LEADING BRANDS
  • AD Agents
  • PD Agents
• Acetylcholine Esterase (AChE) Inhibitors
  • Aricept (Eisai)
  • Exelon (Novartis)
  • Razadyne (Johnson & Johnson/Shire)
• NMDA Antagonist
  • Namenda/Ebixa (Forest/Lundbeck)
• Dopamine Agonists
  • Apokyn (Britannia/Vernalis)
  • Neupro (Schwarz Pharma)
  • Sifrol/Mirapex/Mirapexin (Boehringer Ingelheim)
  • Requip (GlaxoSmithKline)
• Monoaminoxidase (MAO) Inhibitors
  • Azilect (Lundbeck/Teva)
• Catechol-O-Methyltransferase (COMT) Inhibitors
  • Comtan/Comtess & Stalevo (Novartis)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading AD Drugs
  • Sales Forecasts of Current Leading PD Drugs 2005 - 2012
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat AD and PD
• ANALYSIS OF PHASE III DRUGS
  • New Drugs in Phase III Development to Treat AD and PD
  • AD Agents
  • PD Agents
• AD Agents
  • Alzhemed (Neurochem)
  • Flurizan (Myriad Genetics)
  • Phenserine (Axonyx)
  • Xaliproden (sanofi-aventis)
• Parkinson' s Disease
  • E2007 (Eisai)
  • Istradefylline (Kyowa Hakko)
  • Safinamide (Newron)
  • SLV308 (Solvay)
  • Spheramine (Schering AG/Titan)
• GLOBAL SALES FORECASTS OF PHASE III AD and PD DRUGS 2006 - 2012
  • Sales Forecasts of Phase III Developmental AD and PD Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat AD and PD
  • AD Agents
  • PD Agents
• AD agents
  • Bapineuzumab (Wyeth/Elan)
  • Other promising Phase II drugs
  • CX717 (Cortex Pharmaceuticals)
  • EVT 101 (Evotec)
  • Ketasyn (Accera)
  • MEM 1003 (Memory Pharmaceuticals)
  • PBT2 (Prana)
  • SGS-742 (Saegis Pharmaceuticals)
• PD drugs
  • SR 57667 (sanofi-aventis)
  • Talampanel (IVAX)
  • VR040 (Vectura)
• COMPETITOR RATIO ANALYSIS PRODUCTS/DRUGS
  • CR Analysis of AD Agents Approved by 2012 - Based on Drug Class
  • CR Analysis of PD Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of AD and PD Agents Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the AD and PD Market by 2012
• DISCONTINUATION OF DRUGS
  • AD and PD drugs discontinued from clinical development
• NEURODEGENERATIVE APPENDIX 1
  • Phase transition probability
    • Probability of launch
• NEURODEGENERATIVE APPENDIX 2
  • AD Patient Model
    • Summary of AD Patient Population Forecasts
• NEURODEGENERATIVE APPENDIX 3
  • PD Patient Model
    • Summary of PD Patient Population Forecasts
• NEURODEGENERATIVE APPENDIX 4
  • Global AD Drugs Sales 2005-2012
    • Global AD Drug Sales 2005A-2012E
• NEURODEGENERATIVE APPENDIX 5
  • Global PD Drugs Sales 2005-2012
    • Global PD Drug Sales 2005A-2012E
• NEURODEGENERATIVE APPENDIX 6
  • Competitor Ratio Analysis Criteria
    • Key AD & PD Drugs on the Market by 2012
• NEURODEGENERATIVE GLOSSARY
• NEURODEGENERATIVE REFERENCES
• ACRONYMS

SCHIZOPHRENIA

• EXECUTIVE SUMMARY
• THE FACTS
  • What is schizophrenia and why are we interested in it?
    • Symptoms associated with schizophrenia
    • Schematic depicting mood swings in bipolar disorder
• PATIENT STATISTICS
  • Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
  • Summary of patient population forecasts 2005A-2012E
• DRUG GROWTH DRIVERS
• DRUG GROWTH RISKS/DAMPENERS

GLOBAL SCHIZOPHRENIA MARKET

• Global CNS Market (US$68.7 billion)
• GLOBAL SALES SPLIT
  • Global sales split (2005A)
  • Prescription usage split (2005A)
  • The major players
    • Market share of antipsychotic players by sales (Dec 2005A)
    • Market share of antipsychotic players by sales (Dec 2006E)
  • Players and Products in 2005 & 2006
  • Players and Products in 2012
    • Market share of antipsychotic players by sales (Dec 2012E)
• CURRENT TREATMENTS
  • Leading Brands
    • Comparison of leading antipsychotic drugs
  • Current Products Patent Exposure
    • Patent Exposure of Leading Antipsychotic Brands
• ANALYSIS OF LEADING BRANDS
  • Atypical antipsychotics
  • Other Agents
• ATYPICAL ANTIPSYCHOTICS
  • Abilify (Bristol-Myers Squibb/Otsuka)
  • Geodon/Zeldox (Pfizer)
  • Risperdal (Johnson & Johnson)
  • Seroquel (AstraZeneca)
  • Zyprexa (Eli Lilly)
• Other atypical antipsychotics:
  • Serdolect (Lundbeck)
  • Lullan
  • Clozaril/Leponex (Novartis)
  • Solian (sanofi-aventis)
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
  • Sales Forecasts of Current Leading Antipsychotics
  • Model assumptions
• NEW DRUGS IN R&D
  • Drugs in Development to Treat Schizophrenia and Bipolar Disorder
• ANALYSIS OF PHASE III DRUGS
  • Drugs in Phase III Development to Treat Schizophrenia and Bipolar Disorder
  • D/5-HT receptor antagonists
• D/5-HT receptor antagonists
  • Asenapine (Pfizer/Organon)
  • Bifeprunox (Wyeth/Solvay/Lundbeck)
  • Blonanserin (Dainippon Sumitomo)
    • Clinical Efficacy of Blonanserin
  • Iloperidone (Vanda Pharmaceutical)
    • Safety Profile of Iloperidone vs. Approved Antipsychotics
  • Paliperidone (Johnson & Johnson)
• GLOBAL SALES FORECASTS OF PHASE III SCHIZOPHRENIA DRUGS 2006 - 2012
  • Sales Forecasts of Phase III Developmental Antipsychotic Drugs
  • Model assumptions
• ANALYSIS OF PHASE II DRUGS
  • New Drugs in Early Clinical Development to Treat Schizophrenia/Bipolar Disorder
  • Lurasidone (Dainippon Sumitomo/Merck & Co.)
  • Ocaperidone (Neuro3d)
  • SGS518 (Eli Lilly/Saegis Pharmaceuticals)
    • Talnetant (GlaxoSmithKline)
    • Talnetant Efficacy and Safety Profile
  • Talnetant Cognitive Effects
  • ABT-089 (Abbott)
  • ORG 24448 (Akzo Nobel/Cortex Pharmaceuticals)
  • Vabicaserin (Wyeth)
• GLOBAL SALES FORECASTS OF PHASE II ANTIPSYCHOTIC DRUGS 2005-2012
  • Sales Forecasts of Phase II Developmental Antipsychotic Drugs
  • Model assumptions
• COMPETITOR RATIO ANALYSIS
  • CR Analysis of Antipsychotic Agents Approved by 2012 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
  • CR Analysis of Antipsychotics Approved by 2012 - Based on Company
  • WINNERS & LOSERS
    • Summary of Key Companies and Drugs in the Antipsychotic Market by 2012
  • Winners
  • Losers
• DISCONTINUATION OF DRUGS
  • Antipsychotic Drugs Discontinued from Clinical Development
• SCHIZOPHRENIA APPENDIX 1
  • Assessment of antipsychotic efficacy in schizophrenia
  • Assessment of antipsychotic efficacy in bipolar disorder
• SCHIZOPHRENIA APPENDIX 2
  • Phase transition probability
    • Probability of launch
• SCHIZOPHRENIA APPENDIX 3
  • Patient Model
    • Summary of US Schizophrenia Patient Population Forecasts
    • Summary of European (Top 5) Schizophrenia Patient Population Forecasts
    • Summary of Japanese Schizophrenia Patient Population Forecasts
• SCHIZOPHRENIA APPENDIX 4
  • Global Antipsychotic Drug Sales 2005A-2012E
• SCHIZOPHRENIA APPENDIX 5
  • Competitor Ratio Analysis Criteria
    • Key Antipsychotic Drugs on the Market by 2012
• SCHIZOPHRENIA GLOSSARY
• SCHIZOPHRENIA REFERENCES
• ACRONYMS